Preliminary Trial of 3, 4-Diaminopyridine in Patients with Multiple Sclerosis
Ann Neurol 27:421-427, Bever,C.T.,et al, 1990
Orally Administered 4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 27:186-192, Davis,F.A.,et al, 1990
3, 4-Diaminopyridine in the Treatment of Lambert-Eaton Myasthenic Syndrome
NEJM 321:1567-1571, 1607-16081989., McEvoy,K.M.,et al, 1989
4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 21:71-77, Stefoski,D.,et al, 1987
Clinical & Biochemical Correlates of Bradyphrenia in Parkinson's Disease
Neurol 37:1130-1134, Mayeux,R.,et al, 1987
The Clinical Syndrome of Striatal Dopamine Deficiency, Parkinsonism Induced by MPTP
NEJM 312:1418-1421, Burns,R.S.,et al, 1985
Treatment with Oral 4-aminopyridine in Disorders of Neuromuscular Transmission
Neurol 31:265-271, Murray,N.M.F.,et al, 1981
Memory Impairment in Korsakoff's Psychosis:A Correlation with Brain Noradrenergic Activity
Science 202:905-907, McEntee,W.J.,et al, 1978
4-Aminopyridine-A New Drug Tested in the Treatment of Eaton-Lambert Syndrome
JNNP 40:1109, Lundh,H.,et al, 1977